Table 2.
Selected IFN-free treatment options for hepatitis C in patients with liver cirrhosisa
| Genotype |
|||||
|---|---|---|---|---|---|
| 1a | 1b | 2 | 3 | 4 | |
| Compensated | LDV/SOF/RBV | LDV/SOF/RBV | SOF/RBV | SOF/DCV/RBV | LDV/SOF/RBV |
| cirrhosis | 12 wks or | 12 wks or | 12–16 wks | 12–16 wks | 12 wks or |
| (Child A) | AbbVie 3D/RBV | AbbVie 3D | AbbVie 2D/RBV | ||
| 24 wks | 12 wks | 12 wks | |||
| Decompensated | LDV/SOF/RBV | LDV/SOF/RBV | SOF/RBV | SOF/DCV/RBV | LDV/SOF/RBV |
| cirrhosis | 12 wks or | 12 wks or | 16–24 wks | 16–24 wks | 12 wks or |
| (Child B–C) | LDV/SOF | LDV/SOF | LDV/SOF | ||
| 24 wks | 24 wks | 24 wks | |||
a
The listed regimens represent selected options based on national (DGVS) and international (EASL) recommendations as well as on personal judgment. Treatment choice must also consider prior treatments, comorbidities (renal failure, HIV coinfection), and potential drug-drug interactions.
AbbVie 2D = paritaprevir/ritonavir, ombitasvir; AbbVie 3D = paritaprevir/ritonavir, ombitasvir, and dasabuvir; DCV = daclatasvir; LDV = ledipasvir; SOF = sofosbuvir; RBV = ribavirin; wks = weeks.